In a regulatory filing, DexCom (DXCM) stated: “As previously disclosed, DexCom has been involved in global patent litigation with Abbott (ABT) Diabetes Care and its affiliates. Both the Company and Abbott have accused each other of infringing certain patents, and each party has filed counterclaims and actions to invalidate the other party’s patents. On December 20, the Company and Abbott entered into a patent settlement and cross-licensing agreement to resolve all pending patent litigation between the parties. Under the terms of the Agreement, the Company granted Abbott and its affiliates, and Abbott and its affiliates granted the Company and its affiliates, a worldwide, royalty-free, non-exclusive, fully paid license to certain patents and related patent applications. to analyze discovery, including all patents claimed in the Litigation. The Agreement does not obligate the Company or Abbott to pay royalties or any other form of financial compensation. As part of the Agreement, each party, on behalf of itself and its affiliates, has also entered into a covenant not to sue until December 20, 2034; and agreed, on behalf of themselves and their affiliates, to refrain from challenging the patents and patent applications licensed under the Agreement for periods of time that vary depending on the relevant patents or patent applications.”
First published in the fly – the definitive source of real-time breaking financial news affecting the market. Try it now >>
See the top stocks recommended by analysts >>
Read more about DXCM: